▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s private equity firm IMM Investment has offloaded some of its Celltrion Healthcare stocks worth 50 billion won (US$43.84 million) ahead of a planned initial public offering in ...
[ THE INVESTOR ] The recent explosion in data generation combined with fast-improving analytic technologies are beginning to revolutionize the field of medicine and health care, bringing closer the...
[THE INVESTOR] Celltrion Healthcare, the marketing affiliate of biosimilar maker Celltrion , has avoided heavy punishment over accounting irregularities which led to a special audit, allowing the ...
[ THE INVESTOR ] The 2017 Bio International Convention officially kicked off in San Diego, California, on June 19, bringing together thousands of biotech professionals from around the world to exch...
[THE INVESTOR] Korean biotechnology firm Nature Cell said on June 20 that Japan will be the first country to sell its stem cell-based treatment for Alzheimer’s disease patients, starting from as ear...
[THE INVESTOR] Korean vaccine maker Genexine said on June 19 it has received regulatory approval to conduct clinical trials for its DNA vaccine in combination with MSD's cancer immunotherapy Keytr...
[THE INVESTOR] SK Biotek, a wholly owned drug-making subsidiary of SK Holdings, said on June 19 it will acquire US drug maker Bristol-Myers Squibb’s manufacturing plant in Ireland to enter the Europ...
[THE INVESTOR] For the past 11 years, South Korea has recorded the highest suicide rate among Organization for Economic Cooperation and Development countries, with depression and mental illnesses be...
[ THE INVESTOR ] Celltrion Healthcare said on June 16 new clinical data proved its biosimilar Truxima to be fully comparable to its reference medication, Roche’s Rituxan, in terms of efficacy and s...
[THE INVESTOR] Korea’s botulinum toxin maker Medytox has filed a civil lawsuit in the US against Daewoong Pharmaceutical and its US partner Alphaeon for allegedly stealing a key ingredient of its ...
[THE INVESTOR] Celltrion has started searching for a contract manufacturer in North America where it plans to launch two biosimilar products, local media outlet The Bell reported on June 15. “We ar...
[THE INVESTOR] A recent court ruling could advance the US launch of Samsung Bioepis’ Renflexis, biosimilar version of Johnson & Johnson’s blockbuster autoimmune monoclonal antibody treatment Remicad...
[THE INVESTOR] Medytox said on June 13 it has completed late-stage clinical trials for powder-type botulinum toxin in China to expand operations in the country. “China has high market potential fo...
[THE INVESTOR] Celltrion plans to submit biologics license applications for its copy versions of rituximab and trastuzumab to the US regulator over the next few months to begin sales in the US mark...
[ THE INVESTOR ] Medytox, Korea’s largest maker of botulinum toxin, said it has obtained regulatory approval for its new production plant in Osong, North Chungcheong Province. The Korean Ministry ...
The Investor launches weekly 'DECODED X'
Lotte chief becomes white knight for SK’s Toshiba bid
KEPCO nuke chief to meet NuGen CEO
Deutsche Bank may face more civil suits for stock market manipulation
Korea probes Audi A7, A8 for emissions rigging
Kakao spins off mobility biz unit
Facebook mulls data center in Korea
IMM reaps W50b from Celltrion Healthcare ahead of IPO
